Filing Flows › Comparisons › GOSS vs RCUS
Gossamer Bio vs Arcus Biosciences: GOSS and RCUS compared
Gossamer Bio is the larger company: $9.2M of revenue in its latest quarter (Q2 2026) against $9.0M for Arcus Biosciences (Q3 2026). Gossamer Bio is growing faster (-20% against -65% a year earlier).
Where the money goes: GOSS and RCUS
Gossamer Bio (GOSS) · Q2 2026
Gossamer Bio, Q2 2026: revenue $9.2M (-20% year over year), operating margin -282.2%, net earnings $16.9M, operating cash flow −$39.4M. The chart follows the revenue to costs, profit and cash.
Arcus Biosciences (RCUS) · Q3 2026
Arcus Biosciences, Q3 2026: revenue $9.0M (-65% year over year), net loss $128M, operating cash flow −$88.0M. The chart follows the revenue to costs, profit and cash.
| Gossamer Bio (GOSS) | Arcus Biosciences (RCUS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $9.2M | $9.0M |
| Revenue growth, Y/Y | -20% | -65% |
| Operating margin | -282.2% | n/m |
| Net earnings | $16.9M | −$128M |
| Net margin | 182.9% | — |
| Operating cash flow | −$39.4M | −$88.0M |
Where the revenue comes from
Arcus Biosciences
- License and development services: $8.0M (89%)
- Other collaboration: $1.0M (11%)
Questions
Which is bigger, Gossamer Bio or Arcus Biosciences?
Gossamer Bio is the larger company: $9.2M of revenue in its latest quarter (Q2 2026) against $9.0M for Arcus Biosciences (Q3 2026).
Is Gossamer Bio or Arcus Biosciences growing faster?
Gossamer Bio is growing faster (-20% against -65% a year earlier).
More: Gossamer Bio earnings · how Gossamer Bio makes money · Arcus Biosciences earnings · how Arcus Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.